Extended Data Fig. 10: RIPK inhibition normalizes body weight gain in AAV-BR1-Mpro-injected mice. | Nature Neuroscience

Extended Data Fig. 10: RIPK inhibition normalizes body weight gain in AAV-BR1-Mpro-injected mice.

From: The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells

Extended Data Fig. 10

a, RIPKi treatment normalized the body weight gain in AAV-BR1-Mpro-injected mice (N = 5 Ctrl + Vehicle mice, 6 Mpro + Vehicle mice, 6 Ctrl + RIPKi mice, 6 Mpro + RIPKi mice). b, In AAV-BR1-Mpro-injected mice, the cumulative body weight gain over 14 days was normalized by RIPKi treatment (N = 5 Ctrl + Vehicle mice, 6 Mpro + Vehicle mice, 6 Ctrl + RIPKi mice, 6 Mpro + RIPKi mice). Means ± s.e.m. are shown, ** P < 0.01. Detailed information about the exact test statistics, sidedness and values are provided in Supplementary Table 5.

Back to article page